vTv Therapeutics (VTVT) Competitors $15.30 +1.27 (+9.05%) Closing price 03:58 PM EasternExtended Trading$15.30 0.00 (0.00%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTVT vs. CCCC, ACRS, DERM, VYGR, CYBN, LYEL, MEIP, LFVN, CTNM, and TVGNShould you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include C4 Therapeutics (CCCC), Aclaris Therapeutics (ACRS), Journey Medical (DERM), Voyager Therapeutics (VYGR), Cybin (CYBN), Lyell Immunopharma (LYEL), MEI Pharma (MEIP), Lifevantage (LFVN), Contineum Therapeutics (CTNM), and Semper Paratus Acquisition (TVGN). These companies are all part of the "pharmaceutical products" industry. vTv Therapeutics vs. Its Competitors C4 Therapeutics Aclaris Therapeutics Journey Medical Voyager Therapeutics Cybin Lyell Immunopharma MEI Pharma Lifevantage Contineum Therapeutics Semper Paratus Acquisition vTv Therapeutics (NASDAQ:VTVT) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings. Do insiders & institutionals have more ownership in VTVT or CCCC? 17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 4.2% of vTv Therapeutics shares are held by company insiders. Comparatively, 8.7% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is VTVT or CCCC more profitable? vTv Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -325.88%. C4 Therapeutics' return on equity of -53.91% beat vTv Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets vTv TherapeuticsN/A -142.70% -51.71% C4 Therapeutics -325.88%-53.91%-33.26% Which has more risk & volatility, VTVT or CCCC? vTv Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.97, suggesting that its share price is 197% more volatile than the S&P 500. Do analysts prefer VTVT or CCCC? vTv Therapeutics presently has a consensus price target of $35.50, indicating a potential upside of 132.03%. C4 Therapeutics has a consensus price target of $8.00, indicating a potential upside of 240.43%. Given C4 Therapeutics' higher probable upside, analysts plainly believe C4 Therapeutics is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has higher earnings and valuation, VTVT or CCCC? vTv Therapeutics has higher earnings, but lower revenue than C4 Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiovTv Therapeutics$1.02M47.85-$18.46M-$3.01-5.08C4 Therapeutics$34.24M4.88-$105.32M-$1.58-1.49 Does the media favor VTVT or CCCC? In the previous week, vTv Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 8 mentions for vTv Therapeutics and 7 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.18 beat vTv Therapeutics' score of 0.09 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryC4 Therapeutics beats vTv Therapeutics on 10 of the 16 factors compared between the two stocks. Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTVT vs. The Competition Export to ExcelMetricvTv TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.81M$3.08B$5.60B$9.82BDividend YieldN/A2.27%4.60%4.11%P/E Ratio-4.9020.5630.2825.72Price / Sales47.85191.64387.9280.32Price / CashN/A42.0537.7558.93Price / Book3.427.598.456.01Net Income-$18.46M-$54.65M$3.25B$265.06M7 Day Performance7.26%5.43%4.05%2.80%1 Month Performance-8.44%6.75%4.32%1.68%1 Year Performance14.95%31.59%36.25%29.59% vTv Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTVTvTv Therapeutics1.867 of 5 stars$15.30+9.1%$35.50+132.0%+8.5%$48.81M$1.02M-4.909Earnings ReportAnalyst ForecastGap UpCCCCC4 Therapeutics2.1099 of 5 stars$2.42-3.4%$8.00+231.3%-59.1%$177.93M$35.58M-1.53150Earnings ReportAnalyst RevisionACRSAclaris Therapeutics2.6218 of 5 stars$1.64+0.6%$8.71+431.4%+42.9%$176.58M$18.72M-1.20100Earnings ReportDERMJourney Medical1.7129 of 5 stars$7.87+4.0%$9.50+20.7%+50.4%$176.35M$56.13M-20.1890News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeVYGRVoyager Therapeutics3.6971 of 5 stars$3.09-1.8%$13.25+329.4%-44.7%$174.17M$80M-1.67100Analyst RevisionCYBNCybin2.6113 of 5 stars$7.26-2.6%$85.00+1,070.8%N/A$171.26MN/A-1.6650News CoveragePositive NewsLYELLyell Immunopharma3.2991 of 5 stars$10.58-3.6%$15.00+41.8%-60.5%$169.72M$60K-0.42270Trending NewsEarnings ReportGap DownMEIPMEI Pharma2.124 of 5 stars$4.83-6.9%N/A+51.2%$167.99M$65.30M-1.02100Short Interest ↑Gap UpLFVNLifevantage4.2201 of 5 stars$13.76+3.5%$30.50+121.7%+79.6%$167.42M$200.16M19.94260News CoverageCTNMContineum Therapeutics3.4834 of 5 stars$6.43-0.6%$22.50+249.9%-57.3%$167.39M$50M-2.9231Short Interest ↓TVGNSemper Paratus Acquisition3.7539 of 5 stars$0.98+8.8%$10.00+920.4%+48.5%$165.60MN/A0.003 Related Companies and Tools Related Companies CCCC Alternatives ACRS Alternatives DERM Alternatives VYGR Alternatives CYBN Alternatives LYEL Alternatives MEIP Alternatives LFVN Alternatives CTNM Alternatives TVGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTVT) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access